Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Drug development

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background and objectives To assess the incidence of amyloid-related imaging abnormalities (ARIA) in clinical trials of anti-β-amyloid (Aβ) immunotherapy and compare the incidence among different agents and clinical characteristics to identify possible predisposing factors for ARIA. Methods The PubMed and Embase databases were searched for clinical trials of anti-Aβ immunotherapy published on or before January 12, 2022. Phase 2 or 3 randomized controlled trials reporting detailed data sufficient to assess the incidence of ARIA were selected.

What this study adds

Evidence grade: High

This is a trial of 9,429 participants. This meta-analysis assessed the incidence of amyloid-related imaging abnormalities (ARIA) in clinical trials of anti-β-amyloid immunotherapy and compared incidence among different agents and clinical characteristics. Reported effect size: 6.5%; 7.8%; 30.7%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Jeong, S. Y., Suh, C. H., Shim, W. H., Lim, J. S., Lee, J. H., & Kim, S. J. (2022). Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis. Neurology. https://doi.org/10.1212/wnl.0000000000201019

Vancouver

Jeong SY, Suh CH, Shim WH, Lim JS, Lee JH, Kim SJ. Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis. Neurology. 2022. doi:10.1212/wnl.0000000000201019. PMID: 36038268.

BibTeX

@article{jeong2022-36038268,
  author  = {Jeong, S. Y. and Suh, C. H. and Shim, W. H. and Lim, J. S. and Lee, J. H. and Kim, S. J.},
  title   = {{Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis}},
  journal = {Neurology},
  year    = {2022},
  doi     = {10.1212/wnl.0000000000201019},
  pmid    = {36038268},
  url     = {https://doi.org/10.1212/wnl.0000000000201019}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This meta-analysis assessed the incidence of amyloid-related imaging abnormalities (ARIA) in clinical trials of anti-β-amyloid immunotherapy and compared incidence among different agents and clinical characteristics. It focuses on a side effect of treatment rather than on whether the treatment cures or prevents Alzheimer's disease.

Study details

How this study scored 69/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 3 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 69 of 100.69 of 100 points earned31 not earned

Published in a leading specialty journal, and it is a meta-analysis pooling many studies.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies (from PubMed type “Meta-Analysis”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 3 / 4 9,429 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 3 / 7 Cited 39 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 6.5 citations a year over 6 year(s) since 2022
Impact for its field and year 3 / 6 Cited 4.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 2 / 4 Cited 27 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Sang Joon Kim: h-index 50 (OpenAlex, whole career)
Institution's track record 0 / 3 Asan Medical Center: institution h-index 552 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 36038268)
Free to read 0 / 2 Behind a paywall — scores zero
Total 69 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Drug development from nearby years

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Drug development

See all studies in Drug development →